Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.

What Do Studies Say?

The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.

The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.

The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.

The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.

How Was The Study Conducted?

The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.

Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."

Why Does It Work So Well Against Alcoholism?

The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.

However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.

Audrey Leishman, wife of professional golfer Marc Leishman, initially believed she was suffering from the flu after developing common flu-like symptoms. However, her condition rapidly worsened and was later diagnosed as sepsis, a life-threatening medical emergency.

The Virginia woman nearly lost her life, spending 10 days in the intensive care unit (ICU). Following the ordeal, she faced a long recovery and had to relearn how to walk, Fox News reported. Now recovered, Leishman is dedicated to raising awareness about the condition through her nonprofit organization, the Begin Again Foundation. She has also written a children's book aimed at helping families recognize the warning signs.

Symptoms Began After IUD Removal

Leishman faced the ordeal in 2015. She started experiencing symptoms of what she initially thought was an upset stomach a couple of days after having her intrauterine device (IUD) removed, according to the nonprofit Sepsis Alliance.

The next day, the mother of three said she began feeling unwell, experiencing stomach cramps and "severe pain in my right elbow and left big toe," along with a high fever, nosebleeds, diarrhea, and shortness of breath. "I could barely hold my 18-month-old son because I was so weak. My temperature was 102°F," Leishman said.

She eventually went to urgent care, where doctors initially thought she had some form of an autoimmune disease, Fox News reported. As the days went on, Leishman started to feel worse. Her fever spiked higher, and she developed severe stomach issues. "I actually thought I was going a little bit crazy … I hadn't injured myself. I was really confused as to what was going on," Leishman said.

"They took a very long time to figure out what was going wrong with me." "They kept testing me for different things," she continued. "Eventually, they admitted me, and I was in the ICU for a total of 10 days — five of which were in a medically induced coma." During this time, her temperature and heart rate were abnormally high, and her blood pressure was dangerously low.

Sepsis Led to Respiratory Failure

The sepsis ultimately developed into acute respiratory distress syndrome. "I very much remember not being able to breathe," Leishman recalled. "That was by far the scariest part. It got to the point where I had to pause between every word to take a breath, and it was basically like sipping air."

Leishman was eventually diagnosed with sepsis and toxic shock syndrome (TSS), according to Sepsis Alliance.

While she did recover, she was unable to walk, and the first year of recovery was "very difficult." "When I finally did wake up, it was quite the process of relearning how to walk again, dealing with at-home physical therapy and being on a PICC line (peripherally inserted central catheter)," Leishman said.

"My immune system was so compromised that I was sick constantly," she added, noting that although she is now healthy, her memory "is not what it used to be" and that she gets fatigued more often. The original cause of her sepsis remains unclear, she said, but it may have been linked to her recent IUD removal.

Warning Signs of Sepsis

Sepsis is a life-threatening reaction to an infection that harms the immune system, tissues, and organs. It can lead to organ failure or death if not treated urgently, according to the Cleveland Clinic.

According to Sepsis Alliance, the acronym TIME can help people recognize potential warning signs of sepsis and seek urgent medical care.

T — Temperature: Body temperature is unusually high or low.

I — Infection: Signs or symptoms of an infection are present.

M — Mental Decline: Confusion, excessive sleepiness, or difficulty waking up.

E — Extremely Ill: Severe pain, extreme discomfort, or shortness of breath.

Health authorities of the United Kingdom have confirmed that there is a confirmed case of meningitis at the University of Surrey, where a student has been infected with it. Meningitis is one of the most dangerous diseases and containing it comes first for the health authorities.

The UK Health Security Agency (UKHSA) is working to provide preventative antibiotics and vaccinations for close contacts. The authorities are giving great importance to this because of the two earlier deaths in Kent this year.

Jaime Morgan, from UKHSA South East, said: "We understand that news of meningococcal infection can be concerning. However, meningococcal meningitis requires very close contact to spread." She added, "We are working closely with partners and have provided public health advice to close contacts of the case."

Morgan also said that meningococcal disease is known not to spread easily among people, thus a larger possibility of public health loss is unlikely. She also urged the students at the university to be aware of symptoms and to seek medical advice if needed.

Also Read: Why Thousands Of Black Men In The UK Are Now Being Invited For Prostate Cancer Screening?

What Is Meningitis?

Meningitis is an infection of the protective membranes around the spinal cord and the brain. It can become very serious if not treated or diagnosed in time. It is a consequence of bacterial or viral infection. Despite being a rare occurrence, the infection can spread through coughs, sneezes, a cold, or physical contact in the form of kissing.

Understanding the symptoms, causes, and treatment options is important for early diagnosis and timely medical care.

Symptoms Of Meningitis

Health officials urged the public to remain alert to the warning signs of meningococcal meningitis. Common symptoms include:

• Rash
• Headache
• Neck stiffness
• Fever
• Drowsiness
• Nausea or vomiting
• Increased sensitivity to light

How is Meningitis Diagnosed?

Physicians diagnose meningitis using a combination of clinical presentation, laboratory examinations, and imaging tests. Important diagnostic tests are Lumbar Puncture (Spinal Tap), Blood Cultures, and Imaging (CT or MRI Scans).

Though Meningitis is not the only problem of the UKHSA now. Along with other global issues, the United Kingdom is also facing a certain rise in cases of botulism, which is a dreadful disease caused by bacteria and can cause difficulty in breathing, paralysis, and even death. According to the United Kingdom Health Security Agency (UKHSA), recently, two more people from Leeds have come forward with symptoms of this fatal disease.

Last week, a small number of people with symptoms of botulism presented to the National Health Service (NHS) around Leeds. These people observed botulism signs after aesthetic treatments involving botulinum toxin. After a sudden increase in patients of this dreadful disease, the authorities are on alert.

UKHSA urged people to take precautions when seeking cosmetic procedures and has advised medical staff to look out for possible botulism in people who have had recent treatments and have symptoms.

A team of UK scientists has identified 23 unique mutations in the ongoing Ebola outbreak in the Democratic Republic of Congo (DRC) and Uganda, led by the Bundibugyo virus.

The findings, led by scientists from Imperial College London and the University of Oxford, are based on an analysis of 10 available Bundibugyo virus sequences from the Congo and Uganda associated with the current 2026 outbreak, according to Virological.org — an online discussion forum for pathogenic virus sequence data. The forum was launched in November 2014.

The sampled viruses appear to share a most recent common ancestor dating to early-to-mid March 2026, the researchers said.

"The sampled viruses are already genetically diverse. We identified 23 unique mutations across the 10 sequences," said Gina Cuomo-Dannenburg from Imperial College London and Mahan Ghafari from the University of Oxford.

"This level of diversity suggests that the sampled viruses do not represent the very beginning of transmission, but instead reflect an outbreak that had already been circulating, at least partly undetected, for several weeks before sequences became available," they added.

However, the authors noted that "this is an informal analysis and is not intended as a formal preprint or manuscript in its current form" and urged that the estimates "should be interpreted cautiously."

Ebola Cases Continue to Rise

Meanwhile, Congo said on Sunday that the number of confirmed Ebola cases had increased to 515 after 27 new samples tested positive in the previous 24 hours. The confirmed cases include 91 deaths, government data showed.

The Ministry of Health Uganda has confirmed 19 Ebola cases so far, including 14 imported from the DRC and five locally transmitted infections.

According to the World Health Organization, the latest outbreak has resulted in 516 suspected cases and 33 confirmed infections, with as many as 133 deaths reported.

CDC Warns Outbreak Could Rival 2014 Epidemic

The Ebola outbreak spreading through the Democratic Republic of Congo and Uganda could become more devastating than the largest Ebola epidemic in history unless containment efforts improve, according to modelling released by the US CDC.

The models, published in the Morbidity and Mortality Weekly Report, showed that the current outbreak could rival the scale of the 2014 West Africa outbreak, which resulted in more than 28,000 cases and over 11,000 deaths.

"That scale is possible," said Jason Asher, director of the CDC's Center for Forecasting and Outbreak Analytics, during a press briefing.

The worst outcomes could be avoided if "a larger proportion of patients were identified, isolated, and treated," the agency said in its reports.

However, "the public health response to control this outbreak will likely need to be of similar magnitude to the response for the 2014–2016 West Africa Ebola outbreak."

AI-Driven Drug Discovery

Also read: WHO Says Ebola Fight Is Catching Up; Expert Explains Science Behind Patient Recoveries

There are currently no approved treatments specifically for Bundibugyo ebolavirus, despite the existence of some antiviral therapies for other Ebola species. The rare strain is known to kill up to 40 percent of infected patients.

Scientists at the US' Southwest Research Institute (SwRI) have used AI-driven drug discovery platforms to rapidly identify and synthesize 23 antiviral candidates targeting the Bundibugyo Ebola strain currently affecting Congo.

The newly identified compounds are expected to undergo testing against the Bundibugyo virus in the coming weeks.

What Is Ebola?

Ebola is a severe and deadly disease caused by a virus mostly found in Africa. The spread of the disease happens through contact with infected body fluids.

Some symptoms can indicate a possible infection. This includes fever, headache, weakness, vomiting, diarrhea, muscle pain, sore throat, and unexplained bleeding. This eventually leads to severe complications like bleeding, organ failure, and death.